RMD 📈 ResMed - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7611521078
RMD: Portable Diagnostics, Sleep Therapy Devices, Cloud-Based Software Applications
ResMed Inc. is a leading developer, manufacturer, and distributor of medical devices and cloud-based software applications, catering to the diverse needs of the healthcare market. The company's operations are divided into two primary segments: Sleep and Respiratory Care, and Software as a Service. This strategic division enables ResMed to focus on creating innovative products and solutions for a range of respiratory disorders, including sleep apnea, chronic obstructive pulmonary disease (COPD), and other breathing-related conditions. For instance, the company offers ApneaLink Air, a portable diagnostic device that measures various vital signs such as oximetry, respiratory effort, pulse, nasal flow, and snoring, providing healthcare professionals with valuable insights into a patient's sleep patterns.
ResMed's product portfolio also includes NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures Apnea-Hypopnea Index (AHI) based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. This device is designed to provide accurate and reliable data, enabling healthcare professionals to make informed decisions about patient care. Additionally, the company offers AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings, allowing for more efficient and effective patient management. myAir, a personalized therapy management application, is another key product that provides support, education, and troubleshooting tools for patients with sleep apnea, promoting increased patient engagement and improved compliance with treatment plans.
ResMed's software solutions are designed to streamline clinical workflows, improve patient outcomes, and enhance business operations for healthcare providers. The company's out-of-hospital software solutions, such as Brightree business management software and service solutions, cater to providers of home medical equipment (HME), pharmacy, home infusion, orthotics, and prosthetics services. MatrixCare care management and related ancillary solutions are designed for senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations. Furthermore, ResMed offers HEALTHCAREfirst, which provides electronic health record, software, billing and coding services, and analytics for home health and hospice agencies, and MEDIFOX DAN's software solutions, which support the unique needs of these healthcare providers.
ResMed's products and solutions are marketed to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force, ensuring that healthcare professionals have access to the company's innovative products and solutions. With a strong foundation in research and development, ResMed has established itself as a leader in the healthcare technology industry, with a commitment to improving the lives of millions of people worldwide. Founded in 1989 and headquartered in San Diego, California, ResMed Inc. is a publicly traded company listed on the New York Stock Exchange (NYSE) under the ticker symbol RMD, with a web presence at https://www.resmed.com and an ISIN of US7611521078, classified as a common stock under the GICS Sub Industry: Health Care Equipment.
Additional Sources for RMD Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
RMD Stock Overview
Market Cap in USD | 36,600m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 1995-06-02 |
RMD Stock Ratings
Growth 5y | 40.5% |
Fundamental | 89.4% |
Dividend | 54.9% |
Rel. Strength Industry | 1387 |
Analysts | 3.73/5 |
Fair Price Momentum | 233.08 USD |
Fair Price DCF | 237.38 USD |
RMD Dividends
Dividend Yield 12m | 0.85% |
Yield on Cost 5y | 1.35% |
Annual Growth 5y | 3.90% |
Payout Consistency | 100.0% |
RMD Growth Ratios
Growth Correlation 3m | 23.2% |
Growth Correlation 12m | 89.4% |
Growth Correlation 5y | 25.6% |
CAGR 5y | 9.69% |
CAGR/Mean DD 5y | 0.49 |
Sharpe Ratio 12m | 0.96 |
Alpha | 14.12 |
Beta | 0.98 |
Volatility | 43.71% |
Current Volume | 3057.2k |
Average Volume 20d | 818.7k |
As of December 21, 2024, the stock is trading at USD 237.27 with a total of 3,057,163 shares traded.
Over the past week, the price has changed by -4.51%, over one month by -2.75%, over three months by -4.49% and over the past year by +34.66%.
Yes, based on ValueRay Fundamental Analyses, ResMed (NYSE:RMD) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 89.35 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RMD as of December 2024 is 233.08. This means that RMD is currently overvalued and has a potential downside of -1.77%.
ResMed has received a consensus analysts rating of 3.73. Therefor, it is recommend to hold RMD.
- Strong Buy: 5
- Buy: 3
- Hold: 6
- Sell: 0
- Strong Sell: 1
According to ValueRays Forecast Model, RMD ResMed will be worth about 258.7 in December 2025. The stock is currently trading at 237.27. This means that the stock has a potential upside of +9.03%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 253.4 | 6.8% |
Analysts Target Price | 184 | -22.5% |
ValueRay Target Price | 258.7 | 9% |